about
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugateTransforming growth factor β signaling overcomes dasatinib resistance in lung cancerDasatinib as a bone-modifying agent: anabolic and anti-resorptive effectsMolecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.LYN is a mediator of epithelial-mesenchymal transition and a target of dasatinib in breast cancer.Bosutinib reduces the efficacy of Dasatinib in triple-negative breast cancer cell lines.Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunitiesOvercoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectivesAdvanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progressionRapid screening of novel agents for combination therapy in sarcomasAn inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.Molecular basis of cancer-therapy-induced cardiotoxicity: introducing microRNA biomarkers for early assessment of subclinical myocardial injury.Dasatinib blocks transcriptional and promigratory responses to transforming growth factor-beta in pancreatic adenocarcinoma cells through inhibition of Smad signalling: implications for in vivo mode of action.Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.A novel mechanism of dasatinib-induced apoptosis in chronic myeloid leukemia; ceramide synthase and ceramide clearance genes.Bcr-Abl tyrosine kinase inhibitors- current statusDasatinib in the treatment of imatinib refractory chronic myeloid leukemia.Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight.Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.
P2860
Q28473957-DAFA9712-C8EA-40C5-BE0C-7F6DB0539F03Q28542671-2F61D55F-22E8-4436-BB30-CB77A7C5903CQ28730433-7AD7D37E-DB00-4826-AB6F-13B6FB1365FAQ33770326-3BAB20E2-DE75-43A4-9F71-DFB0CDD33646Q33848195-BD2D45AF-BB75-4497-AE42-17814CA35111Q34026441-C7130203-ABE6-424F-BCD8-1405F5F49B82Q34139691-BA84C3CE-B743-44F8-BBA9-1ED4A94B718AQ34491764-AE559B41-E99B-4134-9DF6-FFD8C48F60EBQ35023172-651FB98A-83B4-4735-9D3F-85994260EE2DQ36804215-C8F2AA0F-D4F6-41B5-A259-993122429EFFQ37142455-841AF71B-39B3-4718-BD76-1A4EDAAFE73BQ37298877-D66932F0-E6D6-46D6-896B-0013F7069AE4Q37334825-B1F57183-8B44-48A6-A65A-A75634F3A5A2Q38166071-4A5A8491-F8BF-4834-8468-527F3013FB60Q38818048-38F54028-8EDF-450F-A5E7-C0F868BAD8C4Q39218794-65C2DA3B-D280-4D19-B703-B891A81B1489Q39566737-EC670AA6-831E-4DF4-9459-527176465FB3Q42222524-C36DBE86-AB63-483E-8CF5-D2CD0C2BAD39Q42936651-9F165818-0DE8-41F7-AEA1-6F862824814AQ48168059-BE1BC38A-2D19-43AE-8553-862B0720ABAAQ53260963-C9ECE77D-7CE2-44D5-9C31-CD9520F270C2Q54546815-57C7462B-FF2C-413D-9F00-F9DACEEF03A7Q55280808-65BF9AC5-1EB7-498E-BDBD-AA19D294323E
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Dasatinib: a new step in molecular target therapy
@ast
Dasatinib: a new step in molecular target therapy
@en
Dasatinib: a new step in molecular target therapy
@nl
type
label
Dasatinib: a new step in molecular target therapy
@ast
Dasatinib: a new step in molecular target therapy
@en
Dasatinib: a new step in molecular target therapy
@nl
prefLabel
Dasatinib: a new step in molecular target therapy
@ast
Dasatinib: a new step in molecular target therapy
@en
Dasatinib: a new step in molecular target therapy
@nl
P356
P1433
P1476
Dasatinib: a new step in molecular target therapy
@en
P2093
A Olivieri
L Manzione
P304
P356
10.1093/ANNONC/MDM223
P407
P478
18 Suppl 6
P577
2007-06-01T00:00:00Z